ELV
Elevance Health
$394.82
▲ 1.6%Updated Today 7:15 PM ET
▲ Up 3.3% over the last 12 months
Market Cap
$84.37B
P/E
16.19x
Forward P/E (est.)
17.65x
ROE
11.9%
Revenue Growth
9.4%
EPS Growth
-8.3%
Profit Margin
2.6%
FCF Yield
8.3%
Debt / Equity
0.73x
ROIC
8.0%
Interest Coverage
6.99x
Current Ratio
1.48x
Dividend Yield
1.7%
Implied Growth (rev. DCF)
5.0%
Rating Score
48/100
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what ELV's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. ELV trades near $394.82, above its 50-day average ($373.20) and 200-day average ($340.86). Price above both averages, with the shorter one above the longer, is the textbook definition of an uptrend — momentum favours buyers.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 49 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently negative — short-term momentum is fading.
Volatility — ATR. Average True Range is the typical daily move. ELV's is $11.94 (~3.0% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month ELV found buyers near $384.30 (support) and sellers near $426.98 (resistance); its 52-week range is $273.71–$426.98. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 0.8× the 20-day average — about normal. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
Elevance Health (ELV) is a large-cap company in the Managed Health Care industry, part of the Health Care sector of the S&P 500, with a market value around $84.37B.
In its latest reported year it generated about $199.13B in revenue and $5.66B in net profit.
Our model rates ELV Neutral (48/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
4Y CAGR
9.5%
Revenue moved from $138.64B in 2021 to $199.13B in 2025, a 9.5% compound annual growth rate. The most recent year grew a steady 9.4% year over year. Slower, mature growth is common for established businesses.
Gross Margin
—
Operating Margin
3.6%
Net Margin
2.8%
ROE
11.9%
Elevance Health keeps about 2.6% of each sales dollar as net profit. Return on equity is 11.9% and return on invested capital about 8.0%. Thin margins leave less cushion if costs rise.
Total Debt
$31.12B
Net Debt
$21.46B
Net Debt / EBITDA
2.98x
Debt / Equity
0.73x
Leverage: debt-to-equity is 0.7x, and operating profit covers interest about 7.0x, with a current ratio of 1.5x. That is a moderate, manageable debt load for most businesses. It carries roughly $31.12B of total debt against $9.66B of cash.
Operating CF
$4.29B
Free Cash Flow
$3.17B
FCF Margin
1.6%
In the latest year Elevance Health produced about $4.29B of operating cash flow and $3.17B of free cash flow after capital spending. That is a free-cash-flow yield of about 8.3% on today's price. Strong cash generation funds dividends, buybacks, and reinvestment.
P/E
16.19x
P/S
0.44x
P/B
1.73x
EV / EBITDA
12.33x
ELV trades at 16.2x trailing earnings (about 17.6x on estimated forward earnings), 0.4x sales, and 1.7x book value. Reverse-engineering today's price implies the market expects roughly 5.0% long-term free-cash-flow growth. That is a fairly typical valuation for a profitable company.
Where this stock sits versus what most companies trade at.
Typical ranges are general references (e.g., many stocks trade at ~18–26x earnings), not hard rules. Context only — not investment advice.
How ELV stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (59 S&P 500 companies), ELV ranks #39 of 59 by our overall rating. It trades at a discount versus the sector on earnings (16.2x P/E vs. 25.4x median) with a lower return on equity (11.9% vs. 14.9%) and faster revenue growth (9.4% vs. 7.9%).
P/E vs sector
16.2x
median 25.4x
ROE vs sector
11.9%
median 14.9%
Growth vs sector
9.4%
median 7.9%
Sector rank
#39
of 59 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 59 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$423.25 – $677.20
vs. $394.82 today · expected CAGR 1% – 11%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $217.05B | $236.58B | $257.87B | $281.08B | $306.38B |
| Net income | $6.51B | $7.10B | $7.74B | $8.43B | $9.19B |
| EPS | $29.98 | $32.68 | $35.62 | $38.83 | $42.32 |
| Share price (low) | $299.84 | $326.83 | $356.24 | $388.30 | $423.25 |
| Share price (high) | $479.74 | $522.92 | $569.98 | $621.28 | $677.20 |
| CAGR (low–high) | -24% / 22% | -9% / 15% | -3% / 13% | -0% / 12% | 1% / 11% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for ELV:
- Healthy free-cash-flow yield (~8.3%) funds buybacks and dividends.
- As an established S&P 500 member in Health Care, it brings scale and a long operating history.
The case against ELV:
- Thin net margins (2.6%) leave little room for error.
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Margin risk — thin profitability (2.6%) is vulnerable to cost or pricing pressure.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the picture is mixed: Elevance Health is a large-cap health care business growing at a mature pace, with modest profitability, and a heavier debt load to watch. It trades at 16.2x earnings, which our model scores Neutral (48/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.